36
Participants
Start Date
July 6, 2020
Primary Completion Date
January 31, 2025
Study Completion Date
January 31, 2025
LP-108
For the dose escalation phase, LP-108 will be given once daily at the following dose levels: 100 mg QD, 200 mg QD, 400 mg QD, 600 mg QD, 800 mg QD, 1000 mg QD.
LP-108 and azacitidine
For the dose escalation phase, LP-108 will be given once daily at the following dose levels: 100 mg QD, 200 mg QD, 400 mg QD, 600 mg QD, 800 mg QD, 1000 mg QD, with azacitidine at the standard dose of 75 mg/m2 on Day 1 - Day 7 of each 28-day cycle (weekly schedule) or on Days 1-5, 8, 9 of each 28-day cycle (5-2-2 schedule), according to institutional guidelines.
Hospital San Pedro de Alcántara, Cáceres
Ohio State Comprehensive Cancer Center, Columbus
University of Cincinnati, Cincinnati
University of Michigan, Ann Arbor
MD Anderson Cancer Center, Houston
Institut Català d'oncologia - ICO Badalona, Badalona
Instituto de Investigación Sanitaria La Fe, Valencia
Lead Sponsor
Newave Pharmaceutical Inc
INDUSTRY